1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Approvals

Aleva Neurotherapeutics Scores CE Mark For Deep Brain Stimulation System

 
• By Catherine Longworth

Aleva Neurotherapeutics is taking its directSTIM deep brain stimulation system to the European market following receipt of CE mark. With a fresh round of financing under its belt, Aleva has its eyes on the US next.

Concept of brain wave recording in Parkinson disease surgery. Microelectrode recording in midbrain. Brain model on white background.

Swiss neurostimulation firm Aleva Neurotherapeutics SA has received a CE mark for its flagship product, the directSTIM deep brain stimulation (DBS) system, the company announced on 16 December.

DBS has been shown to improve symptoms of neurological conditions such as Parkinson’s disease, essential tremor and dystonia. Large, invasive...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Policy & Regulation

Increasing Safety Concerns Spur Scrutiny of Device Plastics Use

 
• By Elizabeth Orr

With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.

With LDT Rule DOA, Could FDA Shift Focus To RUOs?

 
• By Brian Bossetta

Now that the US FDA has chosen not to appeal a March ruling effectively killing the agency’s efforts to regulate lab-developed tests as medical devices, will the agency adopt a different strategy to flex its regulatory muscle?

US FDA Unveils Plans To Consolidate Support Services

 
• By Derrick Gingery and Sue Sutter

Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.